Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1842-1847

  Björkholm, Carl ^a   Jardemark, Kent ^a   Schilström, Björn ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidepressive agents; Antipsychotic agents; Dopamine D1 receptors; Electrophysiology; Glutamate receptors; Major depressive disorder

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE 1 RECEPTOR; FLUOXETINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; FACILITATION; IN VITRO STUDY; INTRACELLULAR RECORDING; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PREFRONTAL CORTEX; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION; TISSUE CULTURE TECHNIQUE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; FLUOXETINE; KETAMINE; MALE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; TISSUE CULTURE TECHNIQUES;

EID: 84943359035     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.07.002     Document Type: Article

References (25)

1. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 1997, 283:226-234.
2. Arvanov V.L., Wang R.Y. NMDA-induced response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res. 1997, 768:361-364.
3. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
5. Björkholm C., Frånberg O., Malmerfelt A., Marcus M.M., Konradsson-Geuken Å., Schilström B., Jardemark K., Svensson T.H. Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. Int. J. Neuropsychopharmacol. 2014, [Epub ahead of print]. 10.1093/ijnp/pyu068.
6. Castner S.A., Williams G.V. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cognit. 2007, 63:94-122.
7. Chen L., Yang C.R. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol. 2002, 87:2324-2336.
8. Du Jardin K.G., Liebenberg N., Müller H., Elfving B., Sanchez C., Wegener G. A serotonin-dependent mechanism is essential for the protracted antidepressant-like effect of ketamine in a rat model of depression. Neuroscience Meeting Planner 2014, 2014. Society for Neuroscience, Washington, DC, Program no. 42501/Z34 2014.
9. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:70-75.
10. Huang C.C., Wei I.H., Huang C.L., Chen K.T., Tsai M.H., Tsai P., Tun R., Huang K.H., Chang Y.C., Lane H.Y., Tsai G.E. Inhibition of glycine transporter-i as a novel mechanism for the treatment of depression. Biol. Psychiatry 2013, 74:734-741.
11. Kang H.J., Voleti B., Hajszan T., Rajkowska G., Stockmeier C.A., Licznerski P., Lepack A., Majik M.S., Jeong L.S., Banasr M., Son H., Duman R.S. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 2012, 18:1413-1417.
12. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
13. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
14. Malkesman O., Austin D.R., Tragon T., Wang G., Rompala G., Hamidi A.B., Cui Z., Young W.S., Nakazawa K., Zarate C.A., Manji H.K., Chen G. Acute D-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 2012, 15:1135-1148.
15. Marcus M.M., Jardemark K., Malmerfelt A., Gertow J., Konradsson-Geuken A., Svensson T.H. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence. Synapse 2012, 66:277-290.
16. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
17. Ninan I., Jardemark K.E., Wang R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 2003, 48:66-79.
18. Ninan I., Wang R.Y. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur. J. Neurosci. 2003, 17:1306-1312.
19. Nosyreva E., Szabla K., Autry A.E., Ryazanov A.G., Monteggia L.M., Kavalali E.T. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 2013, 33:6990-7002.
20. Skolnick P. AMPA receptors: a target for novel antidepressants?. Biol. Psychiatry 2008, 63:347-348.
21. Smith W.B., Starck S.R., Roberts R.W., Schuman E.M. Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 2005, 45:765-779.
22. Sun X., Zhao Y., Wolf M.E. Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J. Neurosci. 2005, 25:7342-7351.
23. Tohen M., Case M., Trivedi M.H., Thase M.E., Burke S.J., Durell T.M. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 2010, 71:451-462.
24. Tseng K.Y., O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 2004, 24:5131-5139.
25. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., Bymaster F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23:250-262.